Skip to main content
Top
Published in:

Open Access 28-09-2024 | Juvenile Rheumatoid Arthritis | ORIGINAL ARTICLE

Evaluating treatment practices and challenges in systemic Juvenile Idiopathic Arthritis: a comprehensive survey analysis

Authors: Xiaohua Tan, Xiaozhen Zhao, Jianghong Deng, Chao Li, Junmei Zhang, Shipeng Li, Caifeng Li

Published in: Clinical Rheumatology | Issue 11/2024

Login to get access

Abstract

Objective

This study aims to assess current diagnostic and management for systemic Juvenile Idiopathic Arthritis (sJIA) among physicians, evaluate the challenges encountered in diagnosis and treatment, and identify the educational needs and professional development engagements of physicians managing sJIA.

Methods

A nationwide survey was conducted from November 2023 to March 2024 across tertiary and secondary pediatric and general hospitals in China. The survey targeted physicians with at least three years of specialty experience, resulting in 310 valid responses from 25 provinces, autonomous regions, and municipalities. The survey collected data on diagnostic practices, treatment approaches, and professional development related to sJIA. Data collection was facilitated through WeChat, and statistical analysis was performed using descriptive statistics. Ethical approval was obtained from the Ethics Committee of Beijing Children’s Hospital, with informed consent provided electronically by participants.

Results

The survey indicated that all physicians encountered suspected or confirmed cases of sJIA, highlighting its prevalence and the diagnostic challenges associated. Regarding diagnostic standards, 53.9% of physicians used the “Consensus on the Diagnosis and Treatment of sJIA and Macrophage Activation Syndrome,” 18.1% followed the International League of Associations for Rheumatology (ILAR) standards, and 24.8% adhered to the Pediatric Rheumatology International Trials Organization (PRINTO) standards. In treatment strategies, glucocorticoids and IL-6 receptor monoclonal antibodies were extensively used, with the latter receiving “excellent” and “satisfactory” ratings of 46.5% and 36.1%, respectively, demonstrating high efficacy and acceptance. Main challenges included high treatment costs, complexity of diagnosis, patient compliance issues, and potential long-term side effects of biologics. Additionally, 126 doctors (40.7%) actively participated in more than three academic conferences or systematic learning courses related to sJIA, indicating a strong demand for ongoing education, particularly in new treatment developments and diagnostic skills.

Conclusion

The findings emphasize the necessity for standardized diagnosis and customized treatment plans tailored to patient-specific conditions in managing sJIA.
Key Points
The survey highlights the prevalence and clinical challenges of sJIA among physicians, emphasizing the importance of vigilant diagnosis, multi-system involvement, and differential diagnosis to improve treatment outcomes and patient quality of life.
Literature
1.
go back to reference Bruck N, Schnabel A, Hedrich CM (2015) Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol 159:72–83CrossRefPubMed Bruck N, Schnabel A, Hedrich CM (2015) Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol 159:72–83CrossRefPubMed
2.
go back to reference Murray GM, Vastert SJ, Ramanan AV (2020) Aiming high: quantifying inflammation in systemic onset juvenile idiopathic arthritis (sJIA), a multi-faceted and complex inflammatory disease. Rheumatology 59:3124–3126CrossRefPubMed Murray GM, Vastert SJ, Ramanan AV (2020) Aiming high: quantifying inflammation in systemic onset juvenile idiopathic arthritis (sJIA), a multi-faceted and complex inflammatory disease. Rheumatology 59:3124–3126CrossRefPubMed
3.
go back to reference Kumar S (2016) Systemic Juvenile Idiopathic Arthritis: diagnosis and management. Indian J Pediatr 83:322–327CrossRefPubMed Kumar S (2016) Systemic Juvenile Idiopathic Arthritis: diagnosis and management. Indian J Pediatr 83:322–327CrossRefPubMed
4.
go back to reference Vastert SJ, Kuis W, Grom AA (2009) Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 23:655–664CrossRefPubMedPubMedCentral Vastert SJ, Kuis W, Grom AA (2009) Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 23:655–664CrossRefPubMedPubMedCentral
5.
go back to reference Hinze CH, Foell D, Kessel C (2023) Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol 19:778–789CrossRefPubMed Hinze CH, Foell D, Kessel C (2023) Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol 19:778–789CrossRefPubMed
6.
go back to reference Nijhuis L, Swart JF, Prakken BJ, Van Loosdregt J, Vastert SJ (2023) The clinical and experimental treatment of Juvenile Idiopathic Arthritis. Clin Exp Immunol 213:276–287CrossRefPubMedPubMedCentral Nijhuis L, Swart JF, Prakken BJ, Van Loosdregt J, Vastert SJ (2023) The clinical and experimental treatment of Juvenile Idiopathic Arthritis. Clin Exp Immunol 213:276–287CrossRefPubMedPubMedCentral
7.
go back to reference Ambler WG, Nanda K, Onel KB, Shenoi S (2022) Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. Ann Med 54:1839–1850CrossRefPubMedPubMedCentral Ambler WG, Nanda K, Onel KB, Shenoi S (2022) Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. Ann Med 54:1839–1850CrossRefPubMedPubMedCentral
8.
go back to reference Shakoory B et al (2023) The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis 82:1271–1285CrossRefPubMed Shakoory B et al (2023) The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis 82:1271–1285CrossRefPubMed
9.
go back to reference Martini A et al (2022) Juvenile idiopathic arthritis. Nat Rev Dis Primer 8:5CrossRef Martini A et al (2022) Juvenile idiopathic arthritis. Nat Rev Dis Primer 8:5CrossRef
10.
go back to reference Kaya Akca U et al (2022) The performances of the ILAR, ASAS, and PRINTO classification criteria in ERA patients: a comparison study. Clin Rheumatol 41:1785–1792CrossRefPubMed Kaya Akca U et al (2022) The performances of the ILAR, ASAS, and PRINTO classification criteria in ERA patients: a comparison study. Clin Rheumatol 41:1785–1792CrossRefPubMed
11.
go back to reference Sen ES, Clarke SLN, Ramanan AV (2016) Macrophage activation syndrome. Indian J Pediatr 83:248–253CrossRefPubMed Sen ES, Clarke SLN, Ramanan AV (2016) Macrophage activation syndrome. Indian J Pediatr 83:248–253CrossRefPubMed
12.
go back to reference Henderson LA, Cron RQ (2020) Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Pediatr Drugs 22:29–44CrossRef Henderson LA, Cron RQ (2020) Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Pediatr Drugs 22:29–44CrossRef
13.
go back to reference Poddighe D, Dauyey K (2020) Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. Rheumatol Int 40:695–702CrossRefPubMed Poddighe D, Dauyey K (2020) Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. Rheumatol Int 40:695–702CrossRefPubMed
14.
go back to reference Canna S et al (2009) Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol 7:21CrossRef Canna S et al (2009) Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol 7:21CrossRef
15.
go back to reference Barone P, Pignataro R, Garozzo MT, Leonardi S (2016) IL-6 blockers in systemic onset juvenile idiopathic arthritis. Immunotherapy 8:79–87CrossRefPubMed Barone P, Pignataro R, Garozzo MT, Leonardi S (2016) IL-6 blockers in systemic onset juvenile idiopathic arthritis. Immunotherapy 8:79–87CrossRefPubMed
16.
go back to reference Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B (2017) Tocilizumab (Actemra). Hum Vaccines Immunother 13:1972–1988CrossRef Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B (2017) Tocilizumab (Actemra). Hum Vaccines Immunother 13:1972–1988CrossRef
17.
go back to reference Machado SH, Xavier RM (2017) Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 16:493–500CrossRefPubMed Machado SH, Xavier RM (2017) Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 16:493–500CrossRefPubMed
Metadata
Title
Evaluating treatment practices and challenges in systemic Juvenile Idiopathic Arthritis: a comprehensive survey analysis
Authors
Xiaohua Tan
Xiaozhen Zhao
Jianghong Deng
Chao Li
Junmei Zhang
Shipeng Li
Caifeng Li
Publication date
28-09-2024
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 11/2024
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-07111-2

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more